Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 31511308
Hayward D, et al. (2019) Checkpoint signaling and error correction require regulation of the MPS1 T-loop by PP2A-B56. J Cell Biol 218, 3188-3199 31511308
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T33-p - TTK (human)
Modsite: kFkNEDLtDELsLNK SwissProt Entrez-Gene
Orthologous residues
TTK (human): T33‑p, TTK iso2 (human): T33‑p, TTK (mouse): T32‑p, TTK iso2 (mouse): T32‑p, TTK (rat): T32‑p, TTK (frog): T34‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP2R5D (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA increase siRNA of PP2A-B56 (PPP2R5D)

S37-p - TTK (human)
Modsite: EDLtDELsLNKISAD SwissProt Entrez-Gene
Orthologous residues
TTK (human): S37‑p, TTK iso2 (human): S37‑p, TTK (mouse): S36‑p, TTK iso2 (mouse): S36‑p, TTK (rat): N36‑p, TTK (frog): T38‑p
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP2R5D (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA increase siRNA of PP2A-B56 (PPP2R5D)

T675-p - TTK (human)
Modsite: ANQMQPDttsVVkDS SwissProt Entrez-Gene
Orthologous residues
TTK (human): T675‑p, TTK iso2 (human): T674‑p, TTK (mouse): T674‑p, TTK iso2 (mouse): T648‑p, TTK (rat): T653‑p, TTK (frog): V696‑p
Characterization
Methods used to characterize site in vivo [32P] ATP in vitro, electrophoretic mobility shift, immunoassay, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical), hTERT-RPE1 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE TTK (human)
Comments:  autophosphorylation
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP2R5D (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
KINASE TTK (human) pharmacological inhibitor of upstream enzyme, transfection of inactive enzyme, transfection of constitutively active enzyme, transfection of wild-type enzyme
Comments:  autophosphorylation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA increase siRNA of PP2A-B56 (PPP2R5D)
Downstream Regulation
Effect of modification (function):  activity, induced
Effect of modification (process):  cell cycle regulation, chromatin organization, altered
Comments:  microtubule–kinetochore attachment

T676-p - TTK (human)
Modsite: NQMQPDttsVVkDSQ SwissProt Entrez-Gene
Orthologous residues
TTK (human): T676‑p, TTK iso2 (human): T675‑p, TTK (mouse): T675‑p, TTK iso2 (mouse): T649‑p, TTK (rat): T654‑p, TTK (frog): T697‑p
Characterization
Methods used to characterize site in vivo [32P] ATP in vitro, electrophoretic mobility shift, immunoassay, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), HeLa (cervical), hTERT-RPE1 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE TTK (human)
Comments:  autophosphorylation
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPP2R5D (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
KINASE TTK (human) pharmacological inhibitor of upstream enzyme, transfection of inactive enzyme, transfection of constitutively active enzyme, transfection of wild-type enzyme
Comments:  autophosphorylation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AZ3146 decrease
calyculin_A increase
tautomycetin decrease
siRNA increase siRNA of PP2A-B56 (PPP2R5D)
Downstream Regulation
Effect of modification (function):  activity, induced
Effect of modification (process):  cell cycle regulation, chromatin organization, altered
Comments:  microtubule–kinetochore attachment